Radiation Therapy with Orthovoltage x rays and a Special Collimator

Background

Current radiation therapy is carried out using mostly high energy x-rays. The current MeV x-rays being used have good qualities such as high tissue penetration and a skin-sparing effect. Despite this, several drawbacks are associated with this method; most importantly, the tissue surrounding the target receives radiation, which is damaging to the tissue. These high energy x-rays interact in a scattering mode rather than a photoelectric one, which would be more confined within the target. To address this issue, a grid theory was developed using orthovoltage x-rays. These techniques would be beneficial if they offered tissue-sparing to healthy tissue near the target tissue; without this quality, it doesn't solve the issue of damaging normal tissue. A need for a method of radiotherapy using orthovoltage x-rays for effectively treating tumors is necessary, but the skin and tissue surrounding the target tissue must be spared in order for this method to be effective.

Technology

This technology is a system and method for treating a tumor while sparing the surrounding healthy tissue; it uses orthovoltage x-ray radiation. This technology also discloses how to control the tissue depth reached by the radiation, which is essential in order to protect surrounding healthy tissue. This system uses a multi-aperture collimator near the surface of the skin; this lies within a trajectory of radiation, and generates an array of minibeams, which are designed to merge, forming an effective radiation beam.

Advantages

- Low-cost radiotherapy - Compact solution for radiotherapy- Controlled beams of radiation to minimize damage of surrounding tissue - Tissue depth can be varied from around 1 cm to 10 cm - Beam broaden to less than 1.0 mm during merging process - Angular position of the x-rays can be changed to hit target from different angles

Application

- Treatment of tumors - Treatment of neurological targets, such as: - Brain tumors - Disorders, such as epilepsy and alzheimers

Patent Status

Patented

Stage Of Development

10124194

Licensing Potential

Development partner,Commercial partner,Seeking investment

Licensing Status

Available for partnership.

Additional Info

 

https://stonybrook.technologypublisher.com/files/sites/nknpkjx5stmjsolwronp_nci-vol-8771-300.jpg Please note, header image is purely illustrative. Source: Daniel Sone, NCI, public domain.
Patent Information:
Case ID: R8592
For Information, Contact:
Donna Tumminello
Assistant Director
State University of New York at Stony Brook
6316324163
donna.tumminello@stonybrook.edu
Inventors:
Avraham Dilmanian
Keywords:
Technologies